This is an old revision of this page, as edited by Kazamzam(talk | contribs) at 15:00, 18 November 2022(Removed unreferenced tag). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 15:00, 18 November 2022 by Kazamzam(talk | contribs)(Removed unreferenced tag)
Vesnarinone (INN) is a cardiotonic agent.[1]
A mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure.
References
^Cavusoglu E, Frishman WH, Klapholz M (June 1995). "Vesnarinone: a new inotropic agent for treating congestive heart failure". Journal of Cardiac Failure. 1 (3): 249–257. doi:10.1016/1071-9164(95)90030-6. PMID9420657.